High levels of uPA and PAI-1 predict a good response to anthracyclines

Breast Cancer Research and Treatment

Volumn 121, Issue 3, 2010, Pages 625-626

  Pritchard, Kathleen I ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ESTROGEN RECEPTOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROGESTERONE RECEPTOR; UROKINASE;

ALGORITHM; BREAST CANCER; CANCER GRADING; DRUG CHOICE; DRUG RESPONSE; HUMAN; METHODOLOGY; NOTE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS;

ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; FEMALE; HUMANS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PREDICTIVE VALUE OF TESTS; RESEARCH DESIGN; TUMOR MARKERS, BIOLOGICAL; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 77953121855     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-0795-1     Document Type: Note

References (2)

1. Hayes DF, Trock B, Harris AL. Assessing the clinical impact of prognostic factors: when is "statistically significant" clinical useful? Breast Cancer Res Treat 1998; 52:305-319
2. Matthews J, Altman DG (1996) Interaction 3: how to examine heterogeneity. Brit Med J 313:862